-
April 25, 2019Elpiscience and Bio-Techne Announce Strategic Collaboration
Shanghai and Minneapolis, April 22, 2019, Elpiscience BioPharma and Bio-Techne Corporation today announced that the companies have entered into a strategic collaboration for the development of an...
-
March 14, 2019Elpiscience to Organize “2019 Shanghai Symposium – Novel Targets for Cancer Immunotherapy”
Shanghai, March 14, 2019, Elpiscience Biopharma, Ltd. announces its first Symposium on “Novel Targets for Cancer Immunotherapy”, which will be held on March 24th, at Shanghai Kempinsk...
-
February 22, 2019Elpiscience Announces Clinical Trial Approval of ES101 in China
Shanghai, February 22, 2019, Elpiscience Biopharma, Ltd. announced today that the bispecific antibody ES101 has been approved by the Center for Drug Evaluation (CDE) for clinical trials in China. ES10...
-
December 03, 2018Elpiscience Announces the Completion of Series A+ Financing of 35 Million USD
Shanghai, 3rd December 2018. Elpiscience announced today that it has completed a 35 million USD series A+ round of financing led by Hillhouse Capital, with participation from CDH Investments...
-
October 20, 2018Elpiscience Announces Filing of IND for ES101
Shanghai, 2018.11.20. Elpiscience announced today that it has submitted an Investigational New Drug (IND) application to the Center of Drug Evaluation (CDE) in Beijing to support the initiation o...
-
May 01, 2018Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-106 (ES102) in Greater China
Shanghai and San Diego, May 1st 2018. Elpiscience Biopharmaceutical Ltd (Elpiscience) has entered into a licensing agreement with Inhibrx, Inc., pursuant to which Elpiscience was granted an exclu...